Aeterna Zentaris to Present at Upcoming 6th Annual JMP Securities Healthcare Conference in New York

QUÉBEC CITY, Sept. 21, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its Senior Vice President and Chief Medical Officer, Paul Blake, M.D., will make a corporate presentation at the upcoming 6th Annual JMP Securities Healthcare Conference on Wednesday, September 28, 20011, at 9 a.m. (Eastern) in the Versailles Room of the St. Regis Hotel in New York City.

A live webcast of the presentation will be available on Aeterna Zentaris' website at www.aezsinc.com in the Newsroom section. A replay of the webcast will also be available on the Company's website for a period of 90 days.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, multiple myeloma, endometrial, ovarian, prostate and bladder cancer. The Company's innovative approach of "personalized medicine" means tailoring treatments to a patient's specific condition and to unmet medical needs. Aeterna Zentaris' deep pipeline is drawn from its proprietary discovery unit providing the Company with constant and long-term access to state-of-the-art therapeutic options. For more information please visit www.aezsinc.com.

SOURCE AETERNA ZENTARIS INC.

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.